Phaseline

Companies › Biohaven Therapeutics

Biohaven Therapeutics: clinical trials, targets and expected readouts

7 active drug programs in 10 registered trials: 5 Phase 1, 4 Phase 2, 1 Phase 3; Neurology, Oncology, Metabolic and endocrine, Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BHV-1300
unclear - code-named drug
–Phase 3Graves DiseaseSep 2027
BHV-7000
ATP-sensitive potassium channel opener
Ion channelsPhase 2Focal Epilepsy; Familial ErythromelalgiaDec 2026
BHV-8000–Phase 2Parkinson DiseaseAug 2027
Taldefgrobep Alfa
FGF21 receptor agonist (FGF21 analog)
FGFR1, FGFR4, KLBPhase 2Obesity–
BHV-1400–Phase 1IgA NephropathyJul 2027
BHV-1510–Phase 1Solid TumorFeb 2028
BHV-1530–Phase 1Solid TumorMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07281495Taldefgrobep AlfaPhase 2ObesityMetabolic and endocrineSep 2026
NCT06309966BHV-7000Phase 2Focal EpilepsyNeurologyOct 2026
NCT06132893BHV-7000Phase 2Focal EpilepsyNeurologyDec 2026
NCT07054684BHV-1400Phase 1IgA NephropathyGenitourinaryJul 2027
NCT06976268BHV-8000Phase 2Parkinson DiseaseNeurologyAug 2027
NCT06980649BHV-1300Phase 1Graves DiseaseMetabolic and endocrineSep 2027
NCT07262268BHV-7000Phase 1Familial ErythromelalgiaNeurologyNov 2027
NCT07661056BHV-1300Phase 3Graves DiseaseMetabolic and endocrineJan 2028
NCT06384807BHV-1510Phase 1Solid TumorOncologyFeb 2028
NCT06874335BHV-1530Phase 1Solid TumorOncologyMar 2029

From the company's SEC filings

Cash and short-term investments of $161m on 2026-09-30; operating cash outflow about $459m a year; runway about 4 months at that burn, to Feb 2027; 1 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Targets

Ion channels (1) FGFR1 (1) FGFR4 (1) KLB (1)

Companies with the same targets

Tyra Biosciences Xenon Pharmaceuticals Praxis Precision Medicines AstraZeneca Johnson & Johnson (Janssen) Taiho Oncology Exelixis QED Therapeutics, a BridgeBio company TransThera Sciences (Nanjing) Hutchmed

Companies built like this

Tyra Biosciences Denali Therapeutics Hanmi Pharmaceutical Company Hangzhou Zhongmei Huadong Pharmaceutical Luye Pharma Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.